Provide a brief overview of periciazine, including its mechanism of action, therapeutic uses, evidence supporting its use, clinical considerations, dosage range and dosing schedule, and indicate the regions or countries where it is approved.

Periciazine Overview

Periciazine (also spelled pericyazine) is a first-generation (typical) phenothiazine antipsychotic with particularly sedating properties that is approved in some countries but notably NOT in the United States, and should be considered a second- or third-line option given its significant extrapyramidal side effects and lack of robust efficacy data.

Mechanism of Action

Periciazine is a 3-cyano-10 (3-4'-hydroxypiperidinopropyl) phenothiazine that is pharmacologically similar to chlorpromazine but with distinct receptor binding characteristics 1:

• Primary mechanism: Dopamine receptor blockade (specific subtype analysis has not been performed)
• Unique profile: Induces greater noradrenergic blockade than dopaminergic blockade
• Additional effects: More potent antiemetic, antiserotonin, and anticholinergic activity compared to chlorpromazine
• Sedation: Particularly sedating compared to other phenothiazines

Approved Indications and Geographic Availability

Where It's Approved

Periciazine is NOT approved in the United States 2. The drug label information provided references pyrazinamide (an antituberculosis medication), not periciazine, indicating FDA non-approval.

The medication is available in:

• Australia (documented use in clinical practice) 3, 4
• Russia (documented clinical use) 5
• China (bioequivalence studies conducted) 6
• Likely other countries with less restrictive formularies

Clinical Uses

Based on available evidence, periciazine has been used for:

1. Schizophrenia and schizotypal disorders 1, 5
2. Organic personality disorders with psychopathic-like symptoms 5
3. Personality disorders (dissocial and borderline types with pathocharacterological changes) 5
4. Off-label: Cannabis dependence (in Australian general practice settings) 3
5. Off-label: Methamphetamine withdrawal (as treatment-as-usual comparator) 7

Evidence Supporting Its Use

Quality of Evidence: Very Low

The evidence base for periciazine is extremely limited and of very low quality:

Cochrane Review (2014) 1:

• Only 5 studies from 1965-1980 could be included
• Poor methodological quality (inadequate randomization reporting, allocation concealment unclear, blinding details missing)
• Key finding: Unable to determine effects compared to typical or atypical antipsychotics
• Adverse effects: Higher incidence of extrapyramidal side effects than both typical (RR 0.52,95% CI 0.34-0.80) and atypical antipsychotics (RR 2.69,95% CI 1.35-5.36)
• Conclusion: "We are unable to determine the effects of pericyazine...large, robust studies are still needed"

Naturalistic Studies:

• Cannabis dependence pilot (n=21): Showed reductions in use and psychiatric symptoms, but open-label design prevents causal attribution 3
• Russian inpatient study (n=63): Reported improvement but lacked control group 5
• Methamphetamine withdrawal: Associated with more severe withdrawal syndrome compared to modafinil and mirtazapine 7

Clinical Considerations

Major Concerns

Extrapyramidal Side Effects (EPS):

• Significantly higher risk than both typical and atypical antipsychotics 1
• This contradicts general principles for early psychosis treatment, which emphasize avoiding EPS to encourage adherence 8

Cardiometabolic Risk:

• Recent Australian data (2026) shows elevated cardiometabolic medicine use even with continuous low-dose periciazine 4
• Increased co-dispensing with anti-diabetics, statins, and antihypertensives observed

Limited Evidence Base:

• No high-quality randomized controlled trials
• Does not meet modern treatment-resistance criteria 9
• Not mentioned in contemporary schizophrenia treatment guidelines

When It Might Be Considered

Given the very low quality evidence, periciazine might only be considered when:

• Multiple first- and second-generation antipsychotics have failed (meeting treatment-resistance criteria: at least 2 adequate trials of 6+ weeks at therapeutic doses) 9
• Clozapine is contraindicated or refused
• The medication is locally available and affordable
• Sedation is specifically desired as a therapeutic effect
• Close monitoring for EPS and metabolic effects can be ensured

Dosage Range and Posology

Available Dosing Information

From Australian Practice 3, 4:

• Cannabis dependence protocol: Up to 8 × 2.5 mg tablets daily (maximum 20 mg/day) for 4 weeks
• Low-dose continuous use: 2.5-10 mg/day documented in clinical practice

From Russian Practice 5:

• Dosing not explicitly stated but used in both inpatient (6 weeks) and outpatient (6 months) settings

Pharmacokinetics 6:

• Single oral dose of 10 mg studied in bioequivalence trials
• Unchanged drug predominates in plasma
• Metabolites include 7-hydroxypericyazine and pericyazine sulphoxide

Practical Dosing Approach

If periciazine must be used:

• Start low: 2.5-5 mg daily
• Titrate slowly: Increase by 2.5 mg every 1-2 weeks based on response and tolerability
• Target range: 5-20 mg daily (extrapolated from available literature)
• Maximum: Likely 20-30 mg daily, though formal maximum not established
• Timing: Evening dosing preferred given sedating properties
• Duration: Reassess necessity after 6 weeks; if continuing, monitor closely for metabolic and EPS complications

Critical Pitfalls to Avoid

1. Using as first-line treatment: Contradicts all modern schizophrenia guidelines favoring atypical antipsychotics with lower EPS risk 8
2. Inadequate EPS monitoring: Given significantly elevated risk, regular assessment with standardized scales is essential
3. Ignoring metabolic monitoring: Despite being a typical antipsychotic, metabolic complications are documented 4
4. Prolonged use without reassessment: The evidence base does not support long-term use without regular evaluation of continued necessity
5. Assuming equivalence to other phenothiazines: Its unique receptor profile means it cannot be simply substituted based on chlorpromazine equivalents

Bottom line: Periciazine remains a medication with historical use but insufficient modern evidence to recommend it over contemporary antipsychotics. Its use should be restricted to exceptional circumstances where standard treatments have failed and close monitoring is feasible.